Journal
JOURNAL OF FUNGI
Volume 7, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/jof7030168
Keywords
central nervous system; invasive fungal disease; child; mold; Aspergillus; mucormycetes
Categories
Ask authors/readers for more resources
The incidence of invasive mold disease (IMD) has been increasing, especially in the form of CNS IMD, which is particularly severe, but there is a lack of data on the incidence of CNS IMD in pediatric patients. Further research is needed on the diagnosis and treatment of CNS IMD, with a particular focus on the safety and efficacy in pediatric patients.
The incidence of invasive mold disease (IMD) has significantly increased over the last decades, and IMD of the central nervous system (CNS) is a particularly severe form of this infection. Solid data on the incidence of CNS IMD in the pediatric setting are lacking, in which Aspergillus spp. is the most prevalent pathogen, followed by mucorales. CNS IMD is difficult to diagnose, and although imaging tools such as magnetic resonance imaging have considerably improved, these techniques are still unspecific. As microscopy and culture have a low sensitivity, non-culture-based assays such as the detection of fungal antigens (e.g., galactomannan or beta-D-glucan) or the detection of fungal nucleic acids by molecular assays need to be validated in children with suspected CNS IMD. New and potent antifungal compounds helped to improve outcome of CNS IMD, but not all agents are approved for children and a pediatric dosage has not been established. Therefore, studies have to rapidly evaluate dosage, safety and efficacy of antifungal compounds in the pediatric setting. This review will summarize the current knowledge on diagnostic tools and on the management of CNS IMD with a focus on pediatric patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available